LANADELUMAB SAFETY AND IMMUNOGENICITY: RESULTS FROM THE PHASE 3 HELP STUDY

被引：1
|
作者：
Johnston, D.
Banerji, A.
Riedl, M.
Zuraw, B.
Lumry, W.
Bernstein, J.
Li, H.
Lu, P.
Hao, J.
Gower, R.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2018年 / 121卷 / 05期
关键词：
D O I：
10.1016/j.anai.2018.09.114
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P166
引用
收藏
页码：S36 / S36
页数：1
相关论文
共 50 条
  • [1] LANADELUMAB FOR PREVENTION OF ATTACKS IN HEREDITARY ANGIOEDEMA: RESULTS FROM THE PHASE 3 HELP STUDY
    Banerji, A.
    Riedl, M.
    Bernstein, J.
    Cicardi, M.
    Longhurst, H.
    Zuraw, B.
    Maurer, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S5 - S5
  • [2] Lanadelumab for prevention of attacks in hereditary angioedema: results from the Phase 3 HELP Study
    Banerji, A.
    Riedl, M. A.
    Bernstein, J. A.
    Cicardi, M.
    Longhurst, H. J.
    Zuraw, B. L.
    Bruelle, J.
    Maurer, M.
    SWISS MEDICAL WEEKLY, 2018, 148 : 28S - 29S
  • [3] Lanadelumab And Cardiovascular Risk: Findings From The Phase 3 HELP Study
    Sexton, Daniel J.
    Brown, Nancy J.
    Lumry, William R.
    Gower, Richard G.
    Hao, James
    Lu, Peng
    Zafra, Heidi T. V.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB46 - AB46
  • [4] Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study
    Bernstein, J. A.
    Banerji, A.
    Schranz, J.
    Nurse, C.
    Riedl, M.
    Lu, P.
    ALLERGY, 2018, 73 : 288 - 289
  • [5] Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study
    Cicardi, M.
    Shennak, M.
    Zaragoza-Urdaz, R. H.
    Wang, Y.
    Lu, P.
    ALLERGY, 2018, 73 : 722 - 722
  • [6] Lanadelumab efficacy and safety after switching from androgens: analysis of the phase 3 HELP and HELP OLE studies for hereditary angioedema
    Lumry, William
    Johnston, Douglas
    Riedl, Marc
    Choudhry, Zia
    Nurse, Christina
    Yegin, Ashley
    Juethner, Salome
    Banerji, Aleena
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB166 - AB166
  • [7] Subgroup Analyses From the Phase 3 HELP Study of Lanadelumab for the Prevention of Hereditary Angioedema Attacks
    Banerji, Aleena
    Manning, Michael E.
    Martinez-Saguer, Inmaculada
    Schwartz, Lawrence B.
    Smith, Andrew M.
    Yang, William H.
    Lu, Peng
    Hao, James
    Zuraw, Bruce L.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB43 - AB43
  • [8] LONG-TERM SAFETY OF LANADELUMAB IN HEREDITARY ANGIOEDEMA (HAE): INTERIM RESULTS FROM THE HELP OLE STUDY
    Johnston, D.
    Banerji, A.
    Nurse, C.
    Lu, P.
    Aygoren-Pursun, E.
    Kiani-Alikhan, S.
    Soteres, D.
    Lugar, P.
    Zuraw, B.
    Lockey, R.
    Schwartz, L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S30 - S30
  • [9] Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP Study
    Maurer, M.
    Gierer, S.
    Hebert, J.
    Hao, J.
    Lu, P.
    Bruelle, J.
    Banerji, A.
    SWISS MEDICAL WEEKLY, 2018, 148 : 36S - 36S
  • [10] Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): Results of the phase 3 HELP study
    Maurer, M.
    Gierer, S.
    Hebert, J.
    Hao, J.
    Lu, P.
    Banerji, A.
    ALLERGY, 2018, 73 : 289 - 289
12345